TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07268040: A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07268040 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07268040 Rescue Dossier →